Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Subsequent Events (Details) - USD ($) $ in Millions			5 Months Ended
Subsequent Events (Details) - USD ($) $ in Millions	Jul. 27, 2025	Feb. 07, 2025	Dec. 31, 2025
Sarepta \| Sarepta Collaboration Agreement
Subsequent Event [Line Items]
Future potential milestone payments		$ 10,000.0
Subsequent Event \| Visirna Therapeutics, Inc. \| Sanofi License Agreement \| Forecast
Subsequent Event [Line Items]
Initial transaction price			$ 130.0
Future potential milestone payments			$ 265.0
Subsequent Event \| Sarepta \| Sarepta Collaboration Agreement
Subsequent Event [Line Items]
Future potential milestone payments	$ 200.0
Development milestone payments	$ 100.0